Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MET
REST API REST API
Homo sapiens
MET is differentially expressed in 357 experiments: 171 organism parts: lung, bone marrow, ... (169 more);, 303 disease states: normal, colon carcinoma, ... (301 more);, 121 cell types 585 cell lines 42 compound treatments and 81 other conditions.
Synonyms HGFR, RCCP2
Orthologs Q9BE46_BOVIN (Bos taurus)   Met (Mus musculus)   F6UN86_CIOIN (Ciona intestinalis)   met (Danio rerio)   F1P040_CHICK (Gallus gallus)   Met (Rattus norvegicus)   met (Xenopus laevis)   MET_CANFA (Canis familiaris)   (Compare orthologs)
InterPro Term Plexin_repeat, Plexin-like, Prot_kinase_cat_dom, Semaphorin/CD100_Ag, IPT_TIG_rcpt, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Tyr_kinase_HGF/MSP_rcpt, Se/Thr_kinase-like_dom
Gene Ontology Term plasma membrane, protein binding, response to wounding, flagellum, positive regulation of peptidyl-threonine phosphorylation, cytoplasm, beta-catenin binding, cell proliferation, myoblast proliferation, extracellular space, positive regulation of gene expression, membrane, postsynaptic membrane, male gonad development, protein tyrosine kinase activity, transmembrane receptor protein tyrosine kinase signaling pathway, membrane fraction, glucose homeostasis, activation of MAPK activity, sperm motility, ATP binding, axon guidance, neuron projection, transferase activity, transferring phosphorus-containing groups, multicellular organismal development, cell surface receptor linked signaling pathway, integral to plasma membrane, muscle organ development, postsynaptic density, protein heterodimerization activity, dendrite, positive regulation of DNA replication, receptor activity, nucleotide binding, protein serine/threonine kinase activity, response to drug, adult behavior, transmembrane receptor protein tyrosine kinase activity, integral to membrane, basal plasma membrane, brain development, skeletal muscle tissue development, signal transduction, protein kinase activity, neuron migration, neuronal cell body, positive regulation of peptidyl-serine phosphorylation, positive regulation of neuron projection development, cellular response to glucose stimulus, cellular response to growth factor stimulus, central nervous system neuron differentiation, cell aging, lactation, hepatocyte growth factor receptor signaling pathway, cellular response to peptide hormone stimulus, myotube differentiation, placenta development, pancreas development, excitatory synapse, negative regulation of peptidyl-threonine phosphorylation, response to peptide hormone stimulus, regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling, response to acid, liver development, oligodendrocyte development, positive regulation of glucose transport, protein complex binding, phospholipase binding, positive regulation of mitosis, cellular response to interleukin-6, muscle cell migration, positive regulation of dendrite morphogenesis, protein autophosphorylation, protein phosphorylation, cellular response to inorganic substance, response to organic cyclic compound, phosphatidylinositol 3-kinase binding, cellular response to arsenic-containing substance, hepatocyte growth factor-activated receptor activity
UniProt Accession Q9UEJ3, A1L467, P08581, C9JKM5, B4DPY6, C9JVH4, B4DLF5, E7EQ94
Gene-Disease Assocation HEPATOCELLULAR CARCINOMA, AUTISM, SUSCEPTIBILITY TO, 9; AUTS9, RENAL CELL CARCINOMA, PAPILLARY, 1; RCCP1
Search EB-eye ENSG00000105976
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-11078, E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-GEOD-6573, ... (33 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, ... (47 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-5823, E-GEOD-3529, E-GEOD-20081, E-GEOD-19639
SW480
4
E-GEOD-18005, E-MEXP-1014, E-GEOD-2509, E-MTAB-37
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-96
MDA-MB-231
3
E-GEOD-5823, E-TABM-420, E-MTAB-62
PC3
3
E-GEOD-5258, E-GEOD-14464, E-MEXP-2034
A549
2
E-GEOD-3202, E-GEOD-6013
579 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-2822, ... (57 experiments)

Factor Value U/D Experiments
fibroblast
4
E-GEOD-3920, E-MEXP-466, E-GEOD-3204, E-GEOD-26672
stromal cell
1
3
E-MEXP-2034, E-GEOD-1460, E-GEOD-3998, E-GEOD-10797
human embryonic stem cell
2
E-GEOD-20033, E-GEOD-18265
CD8+ T cell
2
E-AFMX-5, E-MTAB-25
CD34+
2
E-TABM-145, E-AFMX-5
bulge outer root sheath region
1
E-GEOD-3419
115 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-GEOD-16363, E-GEOD-3678, ... (76 experiments)

Factor Value U/D Experiments
colon carcinoma
4
E-MTAB-37, E-GEOD-3726, E-MTAB-62, E-MTAB-57
cervical carcinoma
3
E-MTAB-62, E-MTAB-37, E-MEXP-1331
glioblastoma
1
3
E-MTAB-37, E-MTAB-62, E-GEOD-4412, E-GEOD-4290
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
head and neck squamous cell carcinoma
2
E-GEOD-6631, E-MTAB-62
neuroblastoma
2
E-MTAB-37, E-MTAB-62
297 more value(s).


Compound treatment

studied in E-GEOD-5741, E-GEOD-1417, E-GEOD-697, E-GEOD-5824, E-TABM-868, ... (27 experiments)

Factor Value U/D Experiments
none
2
5
E-GEOD-5824, E-GEOD-412, E-TABM-868, E-GEOD-5099, E-GEOD-1417, ... (7 experiments)
ponasterone A
1
E-GEOD-3113
actinomycin D
1
E-GEOD-6400
sapphyrin PCI-2050
1
E-GEOD-6400
galectin-1
1
E-GEOD-4984
camptothecin
1
E-GEOD-1417
36 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
85
2
1
E-GEOD-21653


Age at onset
studied in E-GEOD-21521

Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-14359, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-2171, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-21374, ... (12 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

crosslinker and crosslinking wavelength
studied in E-GEOD-21918

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-MEXP-2359, E-TABM-145, E-MEXP-958, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-GEOD-22148, ... (10 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-17476, E-GEOD-21750, E-GEOD-22593, E-TABM-321, ... (9 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, E-GEOD-10315, E-TABM-440, ... (15 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716, E-GEOD-2748 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-TABM-26, ... (36 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980, ... (6 experiments)

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426, E-TABM-84

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-1309, E-GEOD-21750, E-GEOD-1657, E-GEOD-923 ... (5 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-19330, E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-548, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

Sex
studied in E-GEOD-19069, E-GEOD-7307

Sirna
studied in E-GEOD-21575, E-GEOD-21574

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271

Processing time: 0.36 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM